

# EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING

M.A. ALLENDE BANDRES, M. ARENERE MENDOZA, P. GOMEZ RIVAS, M.A. ALCACERA LOPEZ, I. VARELA MARTINEZ, R. FRESQUET MOLINA, A. FRUTOS PEREZ-SURIO, L. CAZORLA PODEROSO, T. SALVADOR GOMEZ, J.M. VINUESA HERNANDO, M.D.L.R. GARCIA OSUNA

PHARMACY, HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, ZARAGOZA, SPAIN.

## BACKGROUND

On March 28th 2022, nirmatrelvir/ritonavir was marketed in Spain. The Spanish Agency for Medicines and Medical Devices (AEMPS) established criteria to prioritize its administration in patients at high risk of progression to severe COVID.

## PURPOSE

To assess the **effectiveness and safety** of nirmatrelvir/ritonavir in patients at high risk for severe COVID-19

## MATERIAL AND METHODS

**Prospective descriptive study** from April to August 2022 of patients treated with nirmatrelvir/ritonavir. Sociodemographic variables, vaccination status, hospital admission, high risk factors for progression and concomitant treatment were recorded. Readmissions were recorded within 30 days of the end of antiviral treatment.



## RESULTS

### Characteristics of study patients. (n=53)

Mean age	64 years
Sex	
women	51%
men	49%
Mean number of days from onset of symptoms	1,6

### High-risk criteria

Treatment with myelotoxic chemotherapy	24%
Treatment in the previous 6 months with anti-CD20 drugs	21%
Patients over 80 years vaccinated with some risk factor for progression	14%
Patients with oncohematological treatment a	7%
Treatment in the previous 3 months with inhibitors of the proteinkinase.	7%
Persistent covid (off label)	6%
Others	21%

### CONCOMITANT TREATMENT




- 2 patients received remdesivir + sotrovimab,
- 2 remdesivir
- 2 sotrovimab.

### EFFECTIVENESS

- 4 (7%) were readmitted within 30 days 1 of them with persistent covid.

### SAFETY

- One patient stopped treatment for hives



## CONCLUSIONS

Nirmatrelvir ritonavir has been shown to be a safe and effective drug in high-risk patients of progression to severe covid

